顾淑燕 - 南京大学 - 政府管理学院

个人简介

助理研究员所在院系：政府管理学院劳动人事与社会保障系学术交流 · 2017.08-2018.09 美国杜兰大学公共卫生与热带医学学院访问学者 · 2016.07-2016.10 中国医学科学院肿瘤医院国家癌症中心参与城市癌症早诊早治卫生经济学评估项目主要学术会议 · 2018年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting”，作为第一作者发表1篇会议海报. · 2017年参加国际会议“The International Doctoral Student Conference”，作为第一作者进行口头汇报. · 2016年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 7th Asia-Pacific Conference”，作为第一作者发表2篇会议海报. · 2016年参加国际会议“2016 Chinese Economists Society Annual Conference”，作为第一作者进行口头汇报. · 2016年参加国际会议“Health Technology Assessment International (HTAi) 2016 Annual Meeting”，作为第一作者进行2次口头汇报. · 2015年参加国内会议“中华预防医学会社会医学分会第十一次全国社会医学学术年会”，作为第一作者发表1篇会议论文. · 2015年参加国际会议“Symposium on Social Determinants of Health”，作为嘉宾在会上发言并参与讨论. · 2015年参加国际会议“12th Health Technology Assessment International (HTAi) Annual Meeting”，作为第一作者发表1篇会议海报. · 2014年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Asia-Pacific Conference”，作为第一作者发表1篇会议海报. · 2013年参加国内会议“中华预防医学会第四届学术年会”，作为第一作者发表1篇会议论文.

研究领域

卫生经济学、卫生技术评估、健康行为与生命质量评估、健康管理

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

· Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang, Hengjin Dong. Cost-Effectiveness of Exenatide Twice Daily vs Insulin Glargine as Add-on Therapy to Oral Antidiabetic Agents in Patients with Type 2 Diabetes in China. Diabetes Obes Metab. 2017;19(12):1688-97. · Shuyan Gu, Yiming Mu, Suodi Zhai, Yuhang Zeng, Xuemei Zhen, Hengjin Dong. Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLoS One. 2016;11(11):e0165629. · Shuyan Gu, Huimei Hu, Hengjin Dong. Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension. PharmacoEconomics. 2016;34(6):533-50. · Shuyan Gu, Yuhang Zeng, Demin Yu, Xiaoqian Hu, Hengjin Dong. Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLoS One. 2016;11(11):e0167190. · Shuyan Gu, Huimei Hu, Hengjin Dong. Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension. PharmacoEconomics. 2016;34(8):751-70. · Shuyan Gu, Jing Deng, Lizheng Shi, Yiming Mu, Hengjin Dong. Cost-Effectiveness of Saxagliptin vs Glimepiride as a Second-Line Therapy Added to Metformin in Type 2 Diabetes in China. J Med Econ. 2015;18(10):808-20. · Shuyan Gu, Jihao Shi, Zhiliu Tang, Monika Sawhney, Huimei Hu, Lizheng Shi, Vivian Fonseca, Hengjin Dong. Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: a Meta-Analysis. PLoS One. 2015;10(5):e0126704. · Shuyan Gu, Zhiliu Tang, Lizheng Shi, Monika Sawhney, Huimei Hu, Hengjin Dong. Cost-Minimization Analysis of Metformin and Acarbose in Treatment of Type 2 Diabetes. Value Health Reg Issues. 2015;6:84-8. 摘要收录期刊论文 · Gu S, Wang X, Shi L, Hu X, Gu Y, Huang M, Dong H. VALUING HEALTH-RELATED QUALITY OF LIFE FOR INPATIENTS WITH DIABETES-RELATED COMPLICATIONS IN CHINA. Value in Health, 2018, 21(S1): S77-8. · Gu S, Hu H, Dong H. SYSTEMATIC REVIEW OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Value in Health, 2016,19(3): A118. · Gu S, Dong H. COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS ACARBOSE AS A MONOTHERAPY IN TYPE 2 DIABETES IN CHINA. Value in Health, 2016, 19(7): A898. · Gu S, Shao H, Zeng Y, Shi L, Dong H. COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA. Value in Health, 2016, 19(7): A898. · Gu S, Xu X, Shi L, Sawhney M, Hu H, Dong H. COST MINIMIZATION ANALYSIS OF CLINICAL OPTION SCENARIOS FOR METFORMIN AND ACARBOSE IN TREATMENT OF TYPE 2 DIABETES: BASED ON DIRECT AND INDIRECT TREATMENT COMPARISON RESULTS. Value in Health, 2014, 17(7): A745. 会议论文 · 顾淑燕，董恒进，杨芊，张皓，郜琳，甄雪梅，曾玉航，胡晓茜. 大气细颗粒物污染对居民造成的疾病负担的研究. 中华预防医学会社会医学分会第十一次全国社会医学学术年会, 2015. · 顾淑燕，董恒进，杨芊，刘小方，张皓，胡慧美，王林浩，郜琳. 二甲双胍与阿卡波糖治疗2型糖尿病的文献研究. 中华预防医学会第四届学术年会, 2013.